Latest Kaiser Health News Stories
Health was a featured player in President Donald Trump’s 2019 State of the Union address. The president set goals to bring down prescription drug prices, end the HIV epidemic in the U.S. and cure childhood cancer, among other things. Margot Sanger-Katz of The New York Times, Anna Edney of Bloomberg News and Alice Ollstein of Politico join KHN’s Julie Rovner to discuss these issues and, for “extra credit,” provide their favorite health policy stories of the week. Rovner also interviews KHN senior correspondent Phil Galewitz about the current “Bill of the Month” feature.
The president’s promise to eliminate HIV transmission within 10 years is a goal long sought by advocates, but it won’t be an easy undertaking.
The president laid out a series of goals, including lowering prescription prices, pursuing an end to the HIV epidemic and boosting funding for childhood cancers.
Utah’s Orrin Hatch is leaving the Senate, after 42 years. The Republican led bipartisan efforts to provide health care to more kids and AIDS patients. He also thrived on donations from the drug industry.
Sign-ups for insurance under the Affordable Care Act are still well behind last year’s mark with just a week until the end of open enrollment in most states. The Supreme Court declines a case that could have allowed states to defund Planned Parenthood. And the Trump administration gets hundreds of thousands of comments about its proposed changes to immigration rules that could penalize people who use government-funded health care and other social service programs. Alice Ollstein of Politico, Anna Edney of Bloomberg News and Rebecca Adams of CQ Roll Call join KHN’s Julie Rovner to discuss these issues and, for “extra credit,” provide their favorite health policy stories of the week.
In this episode of KHN’s “What the Health?” Julie Rovner of Kaiser Health News, Rebecca Adams of CQ Roll Call, Kimberly Leonard of the Washington Examiner and Alice Ollstein of Politico discuss how the Democrats’ takeover of the House and other results from the Nov. 6 elections might affect health care, and what Congress may have in store for the lame-duck session.
For over a decade, federal health officials have recommended the practice, known as expedited partner therapy. It is allowed in most states, but many doctors don’t do it — either because of legal or ethical concerns, or because they are unaware of it.
Health insurers and pharmacy benefit managers are exploring how two legal provisions — which have been on the books for decades — could bring down the price tags of certain prescription medications.
California frequently innovates to address its wide-ranging health care needs, but it has not always achieved its aims. A series of articles in the journal Health Affairs shows, among other things, that efforts to care for HIV patients, provide better access to reproductive services for low-income women and fill gaps in primary care have sometimes fallen flat.
Shepherd Smith, a strong supporter of abstinence-only sex education for AIDS, has been close to the new director of the CDC for decades. This connection is just one example of the “new in crowd” surrounding the Trump administration, where politics and religion mix.
It’s getting increasingly difficult for patients to afford Truvada, also known as pre-exposure prophylaxis, or PrEP, because of the drug’s high price and insurance company efforts to restrict the use of coupons that shield patients from it.
Proponents say the residencies provide help dealing with increasingly difficult cases, but some nursing groups contend that the programs are not necessary.
About a dozen states have added hepatitis C to the list of medical conditions for which people can face criminal prosecution if they engage in certain activities like sex without disclosure, needle-sharing or organ donation.
Numerous advocacy groups oppose the recent decision to hold the 2020 International AIDS conference in San Francisco and Oakland, and some argue it shouldn’t be in the U.S. at all. Those who support the decision say the predominantly liberal politics of the region make it an ideal venue for sending a message about the Trump administration’s perceived retreat from leadership on AIDS.
Washington, D.C., is trying to stop new cases of HIV in the district by making sure residents who might be at risk are taking PrEP, medicine that cuts the risk of contracting the virus by 92 percent.
A lawsuit claims that a private company hired by the state public health department to manage enrollment in an AIDS drug assistance program for low-income patients inadvertently allowed unauthorized access to their medical status.
Critics say the Trump administration failed to properly vet Dr. Robert Redfield as they attribute a pattern of “ethically and morally questionable behavior” to him.
The pill, known as PrEP, can reduce the risk of contracting the virus that causes AIDS by 90 percent. Its use has expanded sharply in recent years — but primarily among a white demographic.
In a low-tech snafu, information about HIV treatment was visible through the cellophane window on envelopes sent to about 12,000 consumers.
The hurricane closed pharmacies and clinics for a week or longer. Floodwaters spoiled drugs. People who fled to other states couldn’t get their prescriptions filled for HIV medicine.